|
|
All de la Recherche, 60
Brussels, 1070 Belgium
phone:(32) 2 559 99 99
fax:(32) 2 559 99 00
|
|
| Symbol |
UCB |
| Exchange |
Euronext Brussels |
| Founded |
0 |
| Employees |
|
|
|
| www.ucb-group.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Research of allergic/respiratory diseases and CNS disorders. |
|
| Management |
| Baron Jacobs, Chairman; Countess Diego du Monceau de Bergendal, Vice-Chair; Dr Roch Doliveux, Chief Executive Officer and Chairman of the Executive Committee; H.R.H. Prince; Lorenz of Belgium; Alan John Blinken; Baron Karel Boone; Dr Peter Fellner; Guy Keutgen; Gerhard N. Mayr; Count Arnoud de Pret Roose de Calesberg; Mrs Jean van Rijckevorsel; Ga?tan van de Werve; Prof. Jean-Louis Vanherweghem; Patrick Schwarz-Sch?tte |
| |
|
|
|
|
|
|
|
| Keywords |
| Allergic, respiratory, disease, cns, nervous, immunology, |
|
|
|
| Description |
|
UCB Pharma is a $3 billion niche specialty pharmaceutical company with 8,000 employees engaged in research and development in the fields of allergic/respiratory diseases and disorders of the central nervous system.
Fifth largest biopharmaceutical company in terms of sales. Global presence in more than 40 countries.
Four areas of focus: CNS/neurology allergy/respiratory, inflammation and oncology. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
